专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明专利

AU2002235924A1 METHODS OF IDENTIFYING GENETIC RISK FOR AND EVALUATING TREATMENT OF ALZHEIMER'S DISEASE BY DETERMINING CYP46 GENOTYPE 未知
公开(公告)号：AU2002235924A1
公开(公告)日：2003-06-10
申请号：AU2002235924
申请日：2002-03-01
申请人： UNIV ZUERICH
发明人： PAPASSOTIROPOULOS ANDREAS , STREFFER JOHANNES R , NITSCH ROGER M , HOCK CHRISTOPH
IPC分类号： C12Q1/68 , G01N33/573 , G01N33/68 , G01N33/92
摘要： Based on the unexpected identification of a CYP46 gene polymorphism as a novel genetic risk factor that links cholesterol metabolism to Alzheimer's disease, the present invention provides a method of diagnosing or prognosticating Alzheimer's disease, or determining the propensity or predisposition of a subject to develop Alzheimer's disease. The method comprises detecting the presence or absence of a variation in the CYP46 gene which encodes the enzyme cholesterol 24-hydroxylase.

72. 发明专利

CA2466596A1 CYP46 GENOTYPE DETERMINATION FOR RISK AND TREATMENT EVALUATION OF ALZHEIMER'S DISEASE 未知
公开(公告)号：CA2466596A1
公开(公告)日：2003-06-05
申请号：CA2466596
申请日：2002-03-01
申请人： UNIV ZUERICH
发明人： PAPASSOTIROPOULOS ANDREAS , STREFFER JOHANNES R , HOCK CHRISTOPH , NITSCH ROGER M
IPC分类号： C12Q1/68 , G01N33/573 , G01N33/68 , G01N33/92 , C12Q1/26
摘要： Based on the unexpected identification of a CYP46 gene polymorphism as a nov el genetic risk factor that links cholesterol metabolism to Alzheimer's disease , the present invention provides a method of diagnosing or prognosticating Alzheimer s disease, or determining the propensity or predisposition of a subject to develop Alzheimer s disease. The method comprises detecting the presence or absence of a variation in the CYP46 gene which encodes the enzym e cholesterol 24-hydroxylase.

73. 发明专利

ES2751160T3 Anticuerpos humanos anti-SOD1 未知
公开(公告)号：ES2751160T3
公开(公告)日：2020-03-30
申请号：ES11802074
申请日：2011-12-19
申请人： NEURIMMUNE HOLDING AG , UNIV ZUERICH
发明人： MONTRASIO FABIO , BARENCO MONTRASIO MARIA GRAZIA , GRIMM JAN , NITSCH ROGER , HOCK CHRISTOPH , WELT TOBIAS , MCAFOOSE JORDAN , MAIER MARCEL
IPC分类号： C07K16/40
摘要： Un anticuerpo anti-SOD1 monoclonal humano-murino humano o quimérico o un fragmento de unión a SOD1 del mismo, caracterizado porque el anticuerpo es capaz de unirse a SOD1 mal plegada o agregada; y en donde el anticuerpo reconoce preferentemente la SOD1 mal plegada o agregada sobre los dímeros fisiológicos de SOD1, en donde el anticuerpo o fragmento de unión a SOD1 del mismo se une específicamente a un epítopo de SOD1 que comprende o consiste en la secuencia de aminoácidos GGPKDEERHVG (SEQ ID NO: 51) y comprende en su región variable las seis CDR en el orden que se representa en la Figura 1B (NI-204.12G7).

74. 发明专利

SMT201500186B 未知
公开(公告)号：SMT201500186B
公开(公告)日：2015-10-30
申请号：SM201500186
申请日：2015-08-03
申请人： BIOGEN INTERNAT GMBH , UNIV ZUERICH
发明人： WEIHOFEN ANDREAS , GRIMM JAN , NITSCH ROGER , HOCK CHRISTOPH

75. 发明专利

MX2013003879A ANTICUERPOS ANTI-TAU HUMANOS,. 未知
公开(公告)号：MX2013003879A
公开(公告)日：2014-07-09
申请号：MX2013003879
申请日：2011-10-11
申请人： UNIV ZUERICH
发明人： NITSCH ROGER , HOCK CHRISTOPH , GRIMM JAN , CHEN FENG , BAERISWYL JEAN-LUC
IPC分类号： C07K16/18 , C07K16/46
摘要： Se proporcionan anticuerpos específicos de tau humana así como fragmentos, derivados y variantes de estos así como también métodos relacionados con estos. También se describen ensayos, kits y soportes sólidos relacionados a los anticuerpos específicos para tau. El anticuerpo, cadena(s) de inmunoglobulina, así como también fragmentos de unión, derivados y variantes de estos se pueden usar en composiciones farmacéuticas y de diagnóstico para el diagnóstico e inmunoterapia dirigidos a tau, respectivamente.

76. 发明专利

SG11201401735WA TDP-43 SPECIFIC BINDING MOLECULES 未知
公开(公告)号：SG11201401735WA
公开(公告)日：2014-05-29
申请号：SG11201401735W
申请日：2012-10-26
申请人： BIOGEN IDEC INTERNAT NEUROSCIENCE GMBH , UNIV ZUERICH
发明人： ROGER NITSCH , HOCK CHRISTOPH , BARENCO MONTRASIO MARIA GRAZIA , MONTRASIO FABIO , GRIMM JAN , BAERISWYL JEAN-LUC , WEINREB PAUL , COOMARASWAMY JANAKY , QUINTERO-MONZON OMAR
IPC分类号： C07K16/18
摘要： Provided are novel TDP-43 -specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43 -specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

77. 发明专利

DK2099826T3 ANTI-BETA-AMYLOID-ANTISTOF OG ANVENDELSER DERAF 未知
公开(公告)号：DK2099826T3
公开(公告)日：2014-01-20
申请号：DK08700998
申请日：2008-01-07
申请人： UNIV ZUERICH
发明人： ESSLINGER CHRISTOPH , KNOBLOCH MARLEN , TISSOT KATHRIN , GRIMM JAN , NITSCH ROGER , HOCK CHRISTOPH
IPC分类号： C07K16/18 , A61K39/00 , A61K39/395 , A61P25/28

78. 发明专利

AU2008203703B2 Method of providing disease-specific binding molecules and targets 未知
公开(公告)号：AU2008203703B2
公开(公告)日：2013-09-05
申请号：AU2008203703
申请日：2008-01-07
申请人： UNIV ZUERICH
发明人： ESSLINGER CHRISTOPH , NITSCH ROGER , GRIMM JAN , KNOBLOCH MARLEN , HOCK CHRISTOPH , TISSOT KATHRIN
IPC分类号： C07K16/18 , A61K39/00 , A61K39/395 , A61P25/28
摘要： Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

79. 发明专利

AU2011265453B2 Method of providing disease-specific binding molecules and targets 未知
公开(公告)号：AU2011265453B2
公开(公告)日：2013-05-16
申请号：AU2011265453
申请日：2011-12-22
申请人： UNIV ZUERICH
发明人： NITSCH ROGER , HOCK CHRISTOPH , ESSLINGER CHRISTOPH , KNOBLOCH MARLEN , TISSOT KATHRIN , GRIMM JAN
IPC分类号： C07K16/18 , A61K39/395 , A61P25/28
摘要： INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty) (PCT Rule 44bis) Applicant's or agent's file reference FOR FURTHER ACTION See item 4 below N E30A06/P-WO International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/EP2008/000053 07 January 2008 (07.01.2008) 05 January 2007 (05.01.2007) International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237 Applicant UNIVERSITY OF ZURICH 1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis. 1(a). 2. This REPORT consists of a total of 10 sheets, including this cover sheet. In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead. 3. This report contains indications relating to the following items: Box No. I Basis of the report Box No. 11 Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. IV Lack of unity of invention Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application 4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2). Date of issuance of this report 07 July 2009 (07.07.2009) The International Bureau of WIPO Authorized officer 34, chemin des Colombettes Annes Wittmann-Renis 1211 Geneva 20, Switzerland A W Facsimile No. +41 22 338 82 70 e-mail: pt06.pct@wipo.int Form PCT/IB/373 (January 2004) PA I EN I AUUOPERATIUN TLATY From the INTERNATIONAL SEARCHING AUTHORITY To: POT WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/nonth4'ear) see form PCTASA210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCTASA/220 See paragraph 2 below International application No. International filing date (dayhnonthgear) Priority date (day~nonthgear) PCT/EP2008/000053 07.01.2008 05.01.2007. International Patent Classification (IPC) or both national classification and IPC INV. C07K1 6/18 A61 K39/395 A61 P25/28 Applicant UNIVERSITY OF ZURICH 1. This opinion contains indications relating to the following items: 0 Box No. I Basis of the opinion El Box No. 11 Priority 0 Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability El Box No. IV Lack of unity of invention 0 Box No. V Reasoned statement under Rule 43bis.1 (a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement EJ Box No. VI Certain documents cited E Box No. VII Certain defects in the international application 0 Box No. VIII Certain observations on the international application 2. FURTHER ACTION If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/SA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCTASA/220. 3. For further details, see notes to Form PCTASA/220. Name and mailing address of the ISA: Date of completion of Authorized Officer this opinion European Patent Office see form D-80298 Munich PCTSA21Pez-Mato, Isabel Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 Telephone No. +49 89 2399-2128 WRITTEN OPINION OF THE International application No. INTERNATIONAL SEARCHING AUTHORITY PCT/EP2008)OOO53 Box No. I Basis of the opinion 1. With regard to the language, this opinion has been established on the basis of: 0 the international application in the language in which it was filed El a translation of the international application into , which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1 (b)). 2. El This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43bis.1 (a)) 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of: a. type of material: 0 a sequence listing El table(s) related to the sequence listing b. format of material: 0 on paper 0 in electronic form c. time of filingifurnishing: 0 contained in the international application as filed. 0 filed together with the international application in electronic form. El furnished subsequently to this Authority for the purposes of search. 4. O In addition, in. the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished. 5. Additional comments: WRITTEN OPINION OF THE International application No. INTERNATIONAL SEARCHING AUTHORITY PCT/EP2008/000053 Box No. Ill Non-establishment of opinion with regard to novelty, inventive step and industrial applicability The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of El the entire international application 0 claims Nos. 43-46 because: 0 the said international application, or the said claims Nos. 43-46 relate to the following subject matter which does not require an international search (specify): see separate sheet El the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify): El the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed (specify): El no international search report has been established for the whole application or for said claims Nos. El a meaningful opinion could not be formed without the sequence listing; the applicant did not, within the prescribed time limit: El furnish a sequence listing on paper complying with the standard provided for. in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a formand manner acceptable to it. El furnish a sequence listing in electronic form complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a form and manner acceptable to it. O pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rules 13ter.1(a) or (b). E a meaningful opinion could not be formed without the tables related to the sequence listings; the applicant did not, within the prescribed time limit, furnish such tables in electronic form complying with the technical requirements provided for in Annex C-bis of the Administrative Instructions, and such tables were not available to the International Searching Authority in a form and manner acceptable to it. El the tables related to the nucleotide and/br amino acid sequence listing, if in electronic form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions. El See Supplemental Box for further details WRITTEN OPINION OF THE International application No. INTERNATIONAL SEARCHING AUTHORITY PCT/EP2008D000053 BoxNo. V Rea'soned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. Statement Novelty (N) Yes: Claims 7,8,11-13,20,22-51 No: Claims 1-6.9,10,14-19.21 Inventive step (IS) Yes: Claims No: Claims 1-51 Industrial applicability (IA) Yes: Claims 1-42,47-51 No: Claims 2. Citations and explanations see separate sheet Box No. Vill Certain observations on the international application The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet WRITTEN OPINION OF THE international application No. INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET) PCT/EP2008/000053 Summary The present application relates to a method to obtain binding molecules (in particular, antibodies) that bind to a disorder-related protein. Samples (B cells) from-healthy individuals at risk of developing a disorder or from asymptomatic patients are contacted with diseased and control samples and molecules which bind diseased but not control samples are isolated. The method is specifical

80. 发明专利

CO6230998A2 UN METODO PARA AISLAR UNA MOLECULA DE ENLACE ESPECIFICO DERICADO DE DESORDENES ASOCIADOS A PROTEINAS, MOLECULAS DE ENLACE ESPECIFICAS Y OBJETIVOS 未知
公开(公告)号：CO6230998A2
公开(公告)日：2010-12-20
申请号：CO09081882
申请日：2009-08-05
申请人： UNIV ZUERICH
发明人： NITSCH ROGER , HOCK CHRISTOPH , ESSLINGER CHRISTOPH , KNOBLOCH MARLEN , TISSOT KATHRIN , GRIMM JAN
IPC分类号： A61K39/00 , C07K16/18
摘要： 1.- Un método para aislar una molécula de enlace específico a una proteína asociada con un trastorno, el método caracterizado porque comprende:(a) someter una muestra obtenida de un paciente que está libre de síntomas pero afectado con un trastorno o en riesgo de desarrollarlo, o un paciente con un curso de enfermedad inusualmente estable a un espécimen de células patológicamente alteradas o tejido de características clínicas predeterminadas; e (b) identificar y opcionalmente aislar una molécula de enlace que enlaza al espécimen pero no a las correspondientes células o tejidos de un sujeto saludable.2.- El método de conformidad con la reivindicación 1, caracterizado porque la muestra comprende un fluido corporal o una muestra de células.3.- El método de conformidad con la reivindicación 2, caracterizado porque el fluido corporal es fluido cerebroespinal, plasma u orina 5.4.- El método de conformidad con una de cualquiera de las reivindicaciones 1 a 3, caracterizado porque la molécula de enlace es un anticuerpo.5.- El método de conformidad con una de cualquiera de las reivindicaciones 1 a 4, caracterizado porque la muestra comprende células B o células B de memoria o se deriva de ellas.6.- El método de conformidad con una de cualquiera de las reivindicaciones 1 a 5, caracterizado porque paciente y sujeto, respectivamente, son humanos.7.- El método de conformidad con una de cualquiera de las reivindicaciones 1 a 6, caracterizado porque se ha determinado que el paciente está afectado con un trastorno no manifestado todavía o en riesgo de desarrollar el trastorno por la presencia o ausencia de un marcador sustituto.8.- El método de conformidad con la reivindicación 7, caracterizado porque el marcador sustituto está seleccionado del grupo que consiste en vejez, carga amiloide cerebral, genotipo ApoE, genotipo APP, genotipo PS1, niveles en fluidos corporales de péptido Abeta, isoprostanos, Tau y fosfo-Tau.9.- El método de conformidad con una de cualquiera de las reivindicaciones 1 a 8, caracterizado porque el trastorno está seleccionado del grupo que consiste en trastornos neurológicos, trastornos autoinmunitarios y tumores.10.- El método de conformidad con una de cualquiera de las reivindicaciones 1 a 9, caracterizado porque el trastorno es la enfermedad de Alzheimer.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式